If passed, HB 4491 would significantly alter the regulatory landscape for health benefit plans in the state, specifically around the management of prescription drug formularies. It creates a legal obligation for health carriers to allow medically stable patients to continue their prescribed medications and facilitates a transparent process for exemption requests. This can improve health outcomes for many individuals dependent on specific medications, reinforcing patient rights against arbitrary coverage decisions by insurers.
Summary
House Bill 4491 addresses the issue of non-medical switching in health insurance plans, which often leads to individuals being forced to change their prescribed medications to less expensive alternatives when their health plans modify their formularies. The bill mandates that health carriers must uphold coverage for patients who have been stable on a specific prescription drug, requiring that they cannot impose restrictive changes to coverage for existing patients once the plan year has begun, except under specific conditions. It aims to protect patients' continuity of care by ensuring that medically stable individuals are not switched to different medications without adequate justification.
Contention
Notably, the bill may face opposition from health plans concerned about increased costs associated with maintaining broader coverage for expensive drugs. Critics might argue that the regulations could create financial burdens on insurance programs and thus potentially lead to higher premiums. Supporters, on the other hand, argue that the benefits of patient stability in medications far outweigh financial concerns, reinforcing the importance of tailored healthcare solutions that uphold patient well-being.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.